8,03 €
0,89 % gestern
L&S, 25. Juli, 22:54 Uhr
ISIN
US92556V1061
Symbol
VTRS
Berichte

Viatris Aktie News

Positiv
Market Watch
3 Tage alt
Free cash flow yields show plenty of headroom for these companies to increase their dividends.
Negativ
Barrons
8 Tage alt
The pharmaceutical company says its eye inflammation treatment didn't meet its target.
Negativ
Reuters
8 Tage alt
Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.
Neutral
PRNewsWire
8 Tage alt
PITTSBURGH , July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice dail...
Positiv
Seeking Alpha
10 Tage alt
Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, dividend yield is attractive at 5.26%, and valuation is extremely low versus sector peers. Upcoming FDA approvals and 11 key pipeline assets could drive rapid earnings growth and a major stock price re-...
Positiv
Seeking Alpha
14 Tage alt
High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend dogs could deliver 27% to 53% net gains by July 2026, with lower-than-market volatility. A market correction could make more high-yield stocks fairly priced; currently, only a select few meet the 'd...
Neutral
PRNewsWire
30 Tage alt
MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study Targeting Application To U.S. FDA In Second Half of 2025 PITTSBURGH , June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nas...
Neutral
PRNewsWire
etwa ein Monat alt
PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen